A large randomized, controlled trial (REPRIEVE) conducted by Grinspoon and colleagues showed that in participants living with human immunodeficiency virus (HIV) who are at low-to-moderate risk for cardiovascular disease, those who received pitavastatin had a 35% lower risk of experiencing a major adverse cardiovascular event over a follow-up of approximately five years than those who received placebo.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.